Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

This study has been completed.
Information provided by (Responsible Party):
Protalix Identifier:
First received: August 22, 2011
Last updated: April 18, 2016
Last verified: April 2016
This is a multi-center trial to further extend the assessment of the safety and efficacy of taliglucerase alfa in adult subjects (≥18 years old) with Gaucher disease who have enrolled in Protocol PB-06-003. Subjects will continue to receive an intravenous (IV) infusion of taliglucerase alfa every two weeks. The duration of treatment will be a maximum of 21 months or until taliglucerase alfa is commercially available to the subject at the discretion of the Sponsor.

Condition Intervention Phase
Gaucher Disease
Drug: Taliglucerase alfa
Phase 3

Access to an investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter Extension Study of Taliglucerase Alfa in Adult Subjects With Gaucher Disease

Resource links provided by NLM:

Further study details as provided by Protalix:

Primary Outcome Measures:
  • Spleen Volume [ Time Frame: 60 months ]
    Spleen volume measured by MRI

Secondary Outcome Measures:
  • Liver Volume [ Time Frame: 60 months ]
    Liver volume by MRI

  • Platelet Count [ Time Frame: 60 months ]
    Platelet count measure annually

  • Hemoglobin [ Time Frame: 60 months ]
    Hemoglobin measure yearly

Enrollment: 19
Study Start Date: August 2011
Study Completion Date: September 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Taliglucerase alfa 30 units/kg
Subjects randomized to receive 30 units/kg
Drug: Taliglucerase alfa
Taliglucerase infusion every two weeks for 21 months
Experimental: Taliglucerase alfa 60 units/kg
Subjects randomized to 60 units/kg
Drug: Taliglucerase alfa
Taliglucerase infusion every two weeks for 21 months


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Successfully completed Protocol PB-06-001 and enrolled in Protocol PB-06-003
  • The subject signs an informed consent

Exclusion Criteria:

  • Currently taking another investigational drug for any condition.
  • Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the subject's compliance with the requirements of the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01422187

Sponsors and Collaborators
Study Director: Einat Almon, PhD Protalix Ltd
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Protalix Identifier: NCT01422187     History of Changes
Other Study ID Numbers: PB-06-007
Study First Received: August 22, 2011
Results First Received: November 6, 2015
Last Updated: April 18, 2016

Keywords provided by Protalix:
enzyme replacement therapy

Additional relevant MeSH terms:
Gaucher Disease
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders processed this record on May 25, 2017